Search

Your search keyword '"Durand-Zaleski, Isabelle"' showing total 1,151 results

Search Constraints

Start Over You searched for: Author "Durand-Zaleski, Isabelle" Remove constraint Author: "Durand-Zaleski, Isabelle"
1,151 results on '"Durand-Zaleski, Isabelle"'

Search Results

3. Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial

6. The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective

7. Three-Year Outcomes With Fractional Flow Reserve–Guided or Angiography-Guided Multivessel Percutaneous Coronary Intervention for Myocardial Infarction

8. Somatostatin vs. Octreotide for Prevention of Postoperative Pancreatic Fistula The PREFIPS Randomized Clinical Trial A FRENCH 007 – ACHBT Study

10. Rationale and design of the FRENch CoHort of myocardial Infarction Evaluation (FRENCHIE) study

15. Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial

16. Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial

19. Improving economic evaluations in stroke: A report from the ESO Health Economics Working Group

21. Multicentre medicoeconomic evaluation of cardiac magnetic resonance imaging for predicting coronary artery disease in left ventricular dysfunction: The CAMAREC study design

22. Données et preuves en vie réelle dans l’évaluation des technologies de santé : dans quels cas sont-elles complémentaires, substitutives, ou les seules sources de données par rapport aux essais cliniques ?

25. Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany

30. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis

31. Real-world data and evidence in health technology assessment: When are they complementary, substitutes, or the only sources of data compared to clinical trials?

32. Place des mesures rapportées par les patients (PROMS/PREMS) dans l’évaluation et la valorisation des technologies de santé en France

33. Place of patient-reported outcomes & experiences measurements (PROMS/PREMS) in the assessment and pricing of Health technologies in France

34. Markov Models for Health Economic Evaluations: The R Package heemod

38. Cost-effectiveness of stepwise provisional versus systematic dual stenting strategies in patients with distal bifurcation left main stem lesions: economic analysis of the EBC MAIN trial

39. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

41. How Should we Use Multicolumn Spinal Cord Stimulation to Optimize Back Pain Spatial Neural Targeting? A Prospective, Multicenter, Randomized, Double-Blind, Controlled Trial (ESTIMET Study)

44. Weight telemonitoring of heart failure versus standard of care in a real‐world setting: Results on mortality and hospitalizations in a 6‐month nationwide matched cohort study.

45. The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during the surveillance of patients with cirrhosis.

46. Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection

48. Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study

49. Telemonitoring and experimentation in telemedicine for the improvement of healthcare pathways (ETAPES program). Sustainability beyond 2021: What type of organisational model and funding should be used?

Catalog

Books, media, physical & digital resources